Physician profile
Anthony Lin
NPI 1548258197
$11,213.62
in general payments reported to CMS, 2019-2025
33 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2020: $1,897 · 2021: $1,816 · 2022: $1,391 · 2023: $1,504 · 2024: $1,207 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,775.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,984.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,610.22 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,424.95 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals Lp | $1,177.90 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $886.63 | 2019-2025 | |
| Abbvie INC. | $638.01 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $581.58 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $519.64 | 2019-2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $314.24 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $298.40 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.59 | 2019-2021 | |
| Amgen INC. | $192.48 | 2020-2025 | Repatha, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $170.53 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $164.75 | 2019-2025 | |
| Adlon Therapeutics L.P. | $156.67 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $148.71 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.20 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $117.97 | 2020-2022 | |
| Corcept Therapeutics | $91.33 | 2022-2025 | Korlym |
| Cranial Technologies, INC | $66.54 | 2019-2024 | Doc Band |
| Genentech USA, INC. | $53.97 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $44.16 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $37.24 | 2023 | |
| Azurity Pharmaceuticals, INC. | $35.77 | 2024-2025 | |
| Astellas Pharma US INC | $31.40 | 2023 | Veozah |
| Abbott Laboratories | $23.09 | 2021 | |
| Horizon Therapeutics Plc | $22.48 | 2020 | |
| Arbor Pharmaceuticals, INC. | $18.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.34 | 2021 | |
| Shire North American Group INC | $16.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $14.92 | 2021 | |
| Circassia INC. | $13.02 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.